Capsaicin for Neuropathic Pain: Linking Traditional Medicine and Molecular Biology

Maija Haanpääa Rolf-Detlef Treedeb

a Department of Neurosurgery, Helsinki University Central Hospital, Töölö Hospital, Helsinki, Finland; 
b Lehrstuhl für Neurophysiologie, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany

Introduction

Over the last three millennia, civilizations have attempted to cure sickness with products derived from animal, plant and microbial origins or from mineral sources [1]. About 80% of the populations of some Asian and African countries are estimated to rely on traditional medicines as sources for their primary healthcare. Annual revenues for herbal medicines in Western Europe reached EUR 3.5 billion in 2003–2004 [2]. Although the underlying use of many of these so-called natural products clearly lacks scientific logic, several of them nevertheless became founding platforms for modern drug development throughout the twentieth century [1, 3].

Three classes of analgesic medications are derived from plant ingredients: opiate receptor agonists from poppy seeds, cyclooxygenase inhibitors from willow bark, and capsaicinoids from chili peppers. Capsaicinoid-containing preparations are popular natural medicines for pain syndromes and although the chili peppers from which they are derived (Capsicum spp.) were originally found in the Americas, they are now widespread [4, 5]. Capsaicin of various purities and grades has been widely available in pharmacies as low-to-moderate concentration creams and gels [5–7]. Increased local perfusion and the resulting warming or capsaicin-induced pain leading to counterirritation were initially thought to account for the analgesic effects of capsaicin [5].

Key Words
Capsaicin • Neuropathic pain • TRPV1 • Nociceptor • Hyperalgesia

Abstract
Capsaicin has long been used as a traditional medicine to treat pain and, recently, its mechanism of analgesic action has been discovered. This review article documents the clinical development of capsaicin to demonstrate that pharmacognosy still has a profound influence on modern-day drug development programs. Capsaicin is a highly selective agonist for the transient receptor potential channel vanilloid-receptor type 1 (TRPV1), which is expressed on central and peripheral terminals of nociceptive primary sensory neurons. Knockout studies have revealed the importance of TRPV1 as a molecular pain integrator and target for novel analgesic agents. Topical application of capsaicin at the peripheral terminal of TRPV1-expressing neurons superficially denervates the epidermis in humans in a highly selective manner and results in hypoalgesia. In three recent randomized controlled trials, a patch containing high-concentration capsaicin demonstrated meaningful efficacy and tolerability relative to a low-concentration capsaicin control patch in patients with peripheral neuropathic pain. Data from clinical practice will determine if the high-concentration capsaicin patch is effective in real-world settings.
Cloning of the capsaicin receptor, i.e. the transient receptor potential channel 1 (TRPV1), provided the molecular basis for understanding the various actions of capsaicin [8]. TRPV1 was discovered by an expression cloning strategy utilizing capsaicin-induced increases in intracellular calcium concentration as a marker. The calcium signal not only indicates opening of a nonselective cation channel and depolarization, but also initiation of receptor desensitization and downregulation, and degeneration of epidermal nerve fibers (ENFs), which is referred to as defunctionalization [5, 9, 10]. As a result of neurite degeneration, ENFs become less sensitive to a variety of stimuli (including capsaicin itself), leading to reduced pain responses [5, 10]. A challenge in capsaicinoid drug development was harnessing the desensitizing action of capsaicin without unnecessarily exposing patients to TRPV1 activation-induced pain.

An early therapeutic approach using a low-dose capsaicin cream formulation to defunctionalize nerve endings in human skin required repeated daily applications over weeks [11]. Although pain arising from such topical capsaicin applications is mild, mucous membranes are highly sensitive to the effects. Thus, each topical exposure to capsaicin can result in irritation of the eyes and respiratory tract [12]. A systematic review of clinical trials using low-dose capsaicin creams described moderate-to-poor efficacy in the treatment of chronic neuropathic pain with a number needed to treat of 5.7 [7]. The suboptimal ratio of defunctionalization to irritation with the low-dose capsaicin creams and the lengthy application procedure limited their widespread use [5, 13].

Development of structural analogs of capsaicin that retained its antinoceptive attributes without inducing irritation failed in the late 1980s [5]. Although the capsaicin derivative olvanil was 10 times more potent than capsaicin in TRPV1 activation assays and devoid of pungency, it did not reduce peripheral fiber responsiveness in vitro, possibly because of an alternative mechanism of receptor activation and desensitization [5, 14, 15].

Initiatives to enhance the clinical effectiveness of capsaicin explored use of high doses (10% weight by volume [w/v] and weight by weight [w/w] formulations), which fully desensitize TRPV1-expressing neurons in human skin within a few days or even upon a single application. These creams were useful to determine the actions of TRPV1 expressing neurons in experimental studies of human volunteers [16, 17]. Whereas pain during application is moderate and tolerable in healthy subjects, it may be too strong for patients with sensitization or upregulation of TRPV1. Therapeutic use of high-dose creams was halted because of severe application site-associated pain and the risk of capsaicin contamination to the patient and healthcare professional [16].

Recently, a new dermal patch has been developed containing 8% w/w pure trans-capsaicin in the adhesive layer. This formulation, which enables administration of high-dose capsaicin with a single treatment, is licensed for use in peripheral neuropathic pain in nondiabetic adults in the European Union and for postherpetic neuralgia (PHN) in the USA [18, 19]. Pretreating the affected area of skin with a local anesthetic is advised, although doubts have been raised regarding the benefits of such pretreatment [20, 21].

The aim of the current review is to discuss aspects of capsaicin pharmacology and advances in this challenging area of analgesic drug development. After appraising the neurophysiological effects and mechanism of analgesic action established in preclinical studies, we show that the early concepts regarding capsaicin use have been translated into clinical application through evidence from randomized controlled trials.

**Capsaicin Treatment for Hyperalgesia**

TRPV1 Receptor

Peripheral nociceptive neurons are pseudo-unipolar neurons situated in sensory ganglia that have a single axon which branches within the ganglion into one peripheral and one central axon. TRPV1 functions as a polymodal receptor on the peripheral terminals of primary afferent neurons [22, 23]. On the central terminals, TRPV1 may be involved in modulating signal transmission at the first synapse between the dorsal root ganglion or trigeminal ganglion neurons and the dorsal horn or caudal spinal trigeminal nucleus neurons [24–27].

TRPV1 is a ligand-gated, nonselective cation channel and is one of 30 known members of the TRP ion channel family [8, 28]. TRPV1 is a key receptor involved in the transmission and modulation of pain signals [28], and is an important transducer of noxious stimuli (e.g. heat, low pH) and certain chemicals (including capsaicin). TRPV1 is sensitized by inflammatory mediators responsible for inflammatory pain arising from tissue injury [23, 29]. TRPV1 receptor expression increases in some clinical pain conditions, possibly resulting from increased retrograde transport of nerve growth factor to the cell body [30, 31].

**Preclinical Studies Targeting the TRPV1 Receptor**

Several molecular biology and pharmacological techniques have been employed to elucidate the role of the
TRPV1 receptor in somatosensory pathways. Rodents lacking the TRPV1 channel are not only insensitive to vanilloid-evoked acute pain, but also exhibit impairment in their ability to detect thermal stimuli and to develop thermal hyperalgesia (table 1) [32–34, 55]. However, responsiveness to noxious heat stimuli is not completely lost in TRPV1 knockout mice. Whereas TRPV1 knockout animals lack a component of sensory transduction in an otherwise intact neuronal circuit, intrathecal injection of capsaicin breaks the connection that all capsaicin-sensitive fibers have with the spinal cord [37]. It has been known for some time that intrathecal administration of capsaicin in rats causes long-lasting loss of heat sensitivity [35, 36, 56] and can induce selective degeneration of a distinct population of primary sensory neurons involved in the mediation of chemogenic pain [57]. More recent findings in the mouse indicate that pharmacological ablation of the central branches of TRPV1 nociceptors with capsaicin results in a more complete loss of acute sensitivity to heat pain than that observed in knockout constructs (table 1) [37]. However, it should be noted that 80–90% of neonatal rats desensitized to capsaicin in this way developed wounds, scabs and areas of alopecia [58].

Interestingly, intrathecal administration of resiniferatoxin, a more potent agonist of TRPV1 than capsaicin, to rats and monkeys not only rapidly inhibits nociceptive synaptic transmission but also provides long-lasting analgesia in behavioral models (due to destruction of TRPV1-expressing central sensory nerve terminals) [59, 60]. These data support development of novel analgesics targeting TRPV1-expressing neurons either centrally or peripherally.

The striking difference between the limited effects of TRPV1 gene knockout and the pronounced effects of ablation of TRPV1-positive neurons on nociceptive signal processing is highly relevant for analgesic drug development [61]. While TRPV1 antagonists are anticipated – at best – to mimic the effects of TRPV1 knockout, TRPV1-positive neuron ablation can be mimicked by topical application of TRPV1 agonists to target tissues (skin or mucous membranes).

Studies in Human Volunteers

It is interesting to compare the behavioral effects of topical or intradermal capsaicin in humans with the pronounced changes observed in mice after intrathecal injection of capsaicin, as these procedures involve exposure to capsaicin at the two terminals of the same neuron. Topical exposure to capsaicin in humans leads initially to nociceptor firing and a period of enhanced sensitivity to painful heat stimuli. A refractory period follows during which individuals are relatively resistant to capsaicin and heat but not pinprick stimuli [17, 38, 62, 63], consistent with the existence of a TRPV1-negative population of nociceptors that appear to be specialized for mechanical pain. Defunctionalization following continuous capsaicin exposure is accomplished via a TRPV1 receptor-mediated massive influx of calcium ions into the neuron [64] and the ensuing activation of calcium-sensitive proteases (among other mechanisms), which results in reversible neurite degeneration that can be visualized as reduction in ENFs (fig. 1) [10, 42, 43].

Fig. 1. Intraepidermal nerve fibers retract following high-dose topical capsaicin treatment. Reprinted from Kennedy et al. [43] with permission from Elsevier.
### Table 1. Summary of selected study using capsaicin in animals and humans

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>Intervention</th>
<th>Sample size, n</th>
<th>Main study results</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Animal studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caterina et al. [32], 2000</td>
<td>Murine case-control</td>
<td>TRPV1 knockout 2–9 depending on the test</td>
<td>1) Normal response to noxious mechanical stimuli 2) No vanilloid-evoked pain behavior 3) Impaired detection of painful heat 4) Modest thermal hypersensitivity in a tissue injury and neurogenic inflammation model</td>
<td>1) TRPV1 critical for certain modalities of pain sensation and tissue injury-induced thermal hyperalgesia 2) The TRPV1 receptor becomes a target for drug development</td>
<td></td>
</tr>
<tr>
<td>Davis et al. [33], 2000</td>
<td>Murine case-control</td>
<td>TRPV1 knockout 8–20 depending on the test</td>
<td>1) Dorsal root ganglion cells lacked characteristic responses to capsaicin, acid and heat 2) Treated mice were behaviorally normal (even to acute noxious thermal stimuli) except for an absent response to carrageenan</td>
<td>TRPV1 is required for inflammatory sensitization to noxious thermal stimuli but alternative mechanisms are sufficient for normal noxious heat perception</td>
<td></td>
</tr>
<tr>
<td>Bolcskei et al. [34], 2005</td>
<td>Murine case-control</td>
<td>TRPV1 knockout 6–12 depending on the test</td>
<td>1) Treated mice were behaviorally normal to formalin-induced acute nocifensive behavior and to carrageenan-evoked and partial sciatic nerve lesion-induced mechanical hyperalgesia 2) Thermal and mechanical hyperalgesia induced by a mild heat injury was reduced among treated mice 3) Mechanical hyperalgesia increased among treated mice in a systemic polyneuropathy model</td>
<td>TRPV1 receptor plays a pro-nociceptive role in certain models of acute tissue injury but, conversely, may reduce hyperalgesia under chronic polyneuropathic conditions</td>
<td></td>
</tr>
<tr>
<td>Yaksh et al. [35], 1979</td>
<td>Murine case-control</td>
<td>Intrathecal capsaicin (TRPV1 neuron destruction) 3–20 depending on the test</td>
<td>1) Prolonged increase in thermal and chemical pain thresholds 2) No change in responses to noxious mechanical stimuli 3) Treated mice had reduced spinal substance P levels</td>
<td>Thermal and chemical analgesia was not accompanied by changes in response to mechanical stimuli or in loss of motor coordination</td>
<td></td>
</tr>
<tr>
<td>Nagy et al. [36], 1981</td>
<td>Murine case-control</td>
<td>Intrathecal capsaicin (TRPV1 neuron destruction) 37</td>
<td>1) Some treated mice had profound thermal analgesia 2) Responders with thermal analgesia had similar spinal levels of substance P and somatostatin to nonresponders</td>
<td>Intrathecal capsaicin-induced depletion of spinal substance P levels are not sufficient to rationalize the alterations in noxious thermal thresholds</td>
<td></td>
</tr>
<tr>
<td>Cavanaugh et al. [37], 2009</td>
<td>Murine case-control</td>
<td>Intrathecal capsaicin (TRPV1 neuron destruction) and/or DTX (Mrgprd neuron destruction) 3–10 depending on the test</td>
<td>1) Behavioral responses to noxious heat (but not mechanical and cold stimuli) eliminated in capsaicin-treated mice 2) Selective reduction of behavioral responses to noxious mechanical stimuli in mice receiving DTX (residual sensitivity remained) 3) No additional behavioral deficits with the additive phenotype</td>
<td>1) The brain can distinguish between different noxious stimuli at the earliest stages of sensory processing 2) Residual mechanical sensitivity in DTX-treated mice attributed to the presence of cutaneous C fibers and/or of myelinated afferent neurons lacking TRPV1 and Mrgprd</td>
<td></td>
</tr>
<tr>
<td><strong>Human healthy volunteer studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simone and Ochoa [38], 1991</td>
<td>Double-blind, vehicle-controlled</td>
<td>Capsaicin cream 0.075% w/w 4 times daily for 6 weeks</td>
<td>1) Mean detection threshold for heat pain elevated by 3.5°C after 6 weeks of application 2) Mean magnitude of suprathreshold heat pain diminished progressively after 1 week 3) Detection thresholds for touch, cold, low temperature and mechanically evoked pain were not altered by topical capsaicin</td>
<td>Prolonged low-concentration capsaicin selectively diminishes heat pain sensations and neurogenic vasodilatation in a reversible manner</td>
<td></td>
</tr>
<tr>
<td>Reference</td>
<td>Study design</td>
<td>Intervention</td>
<td>Sample size, n</td>
<td>Main study results</td>
<td>Comment</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------------------</td>
<td>--------------------------------------------------------</td>
<td>----------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Beydoun et al. [39], 1996      | Randomized, double-blind, vehicle-controlled | Capsaicin cream 0.075% w/w 3 times daily for 5 weeks | 5              | 1) Magnitude estimation of suprathreshold heat pain, laser pulses and LEPs significantly decreased  
2) Topical capsaicin not associated with changes in light touch, deep pain and mechanical pain thresholds | 1) Maximal thermal analgesia observed after 4 weeks of treatment  
2) All effects were reversible upon discontinuation of therapy  
3) Capsaicin unlikely to target C or Aδ fiber mechanoreceptors |
| Nolano et al. [10], 1999       | Open-label, controlled        | Capsaicin cream 0.075% w/w 4 times daily for 3 weeks   | 10             | 1) Change from baseline for skin data: 74% decrease in ENF density on day 3; 79 and 82% reduction in ENF density from blisters and biopsies, respectively, at week 3  
2) QST findings: capsaicin significantly reduced sensitivity to thermal (noxious heat and, to a lesser extent, cold) and mechanical stimuli, and increased tactile threshold relative to untreated sites | 1) Capsaicin effects on the skin were generally reversible  
2) Hypoalgesia appeared to be mediated via ENF degeneration  
3) These objective data did not translate into clinical effectiveness for capsaicin cream |
| Khalili et al. [40], 2001      | Open-label, single-center, controlled | Capsaicin cream 0.075% w/w 4 times daily for 7 days | 12             | 1) Almost complete disappearance of ENFs after 3 days of capsaicin treatment  
2) Dramatic reduction in heat pain (with small but not large thermode)  
3) Sharp pain sensation reduced but detection threshold for tactile sensation unchanged | 1) ENFs gradually reappeared after cessation of therapy  
2) Small thermodes may be clinically useful for detecting early peripheral neuropathies affecting unmyelinated nerve fibers and monitoring treatment response |
| Ragé et al. [41], 2010         | Open-label, single-center, controlled | Constant exposure to capsaicin cream 0.075% w/w for 3 days | 12             | 1) By day 1 postcapsaicin: cutaneous thermal sensitivity and LEPs were reduced, and PGP9.5, TRPV1 and GAP-43 immunoreactive nerve fibers were almost completely absent  
2) LEPs had fully recovered by day 12 postcapsaicin, but PGP9.5 and TRPV1 ENF continued to be significantly decreased at day 34 postcapsaicin  
3) Cold detection threshold increased (became cooler) relative to baseline as did warm detection threshold | 1) A good correlation was observed between LEPs and GAP-43 staining, in contrast to PGP9.5 and TRPV1  
2) Assessing skin biopsies by PGP9.5 immunostaining alone may miss significant diagnostic and prognostic information regarding regenerating ENFs |
| Magerl et al. [17], 2001       | Vehicle-controlled            | Capsaicin cream 10% w/w; A-fiber conduction blockade   | 20             | Capsaicin-insensitive A-fiber nociceptors have the primary role in signaling pain to mechanical stimuli | The psychophysical data rationalize why topical capsaicin has minimal effects on responses to mechanical stimuli |
| Malmberg et al. [42], 2004     | Randomized, controlled, single-center | Single application (30, 60 or 120 min) of capsaicin 8% w/w patch, capsaicin 0.04% w/w patch or placebo | 20             | 1) 7 days post-application, a significant reduction in heat (by 1.5°C) but not cold sensitivity, and reduction of ENF immunostaining with capsaicin 8% w/w patch applied for 60 or 120 min  
2) Thermal threshold detection and ENF immunostaining were not significantly different from placebo for sites exposed to capsaicin 0.04% w/w patches for 120 min | First study to show the feasibility of a high-concentration capsaicin patch in the treatment of peripheral neuropathic pain |
Table 1 (continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>Intervention</th>
<th>Sample size, n</th>
<th>Main study results</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kennedy et al. [43], 2010</td>
<td>Randomized, controlled, open-label, single-center</td>
<td>Single application of capsaicin 8% w/w patch</td>
<td>36</td>
<td>1) 1 week postapplication: ~80% reduction in ENF density compared with unexposed sites; ~8% increase from baseline in tactile thresholds; ~15% reduction in the proportion of stimuli reported as sharp mechanical pain 2) 12 weeks postapplication: ENF regeneration evident; sharp mechanical pain sensation and tactile thresholds not different to unexposed sites 3) 24 weeks postapplication: 93% of ENFs had recovered 4) No significant changes in heat- or cold-detection thresholds observed at any time point</td>
<td>1) Confirmation and extension of results by Malmberg et al. [42], 2004 2) Capsaicin 8% w/w patch was generally well tolerated</td>
</tr>
<tr>
<td>Bernstein et al. [44], 1989</td>
<td>Randomized, double-blind, vehicle-controlled study in PHN</td>
<td>Capsaicin cream 0.075% w/w vs. vehicle 3–4 times daily for 6 weeks</td>
<td>32</td>
<td>1) Reduction in physician global rating of pain (77 vs. 31%; p &lt; 0.05) 2) Reduction in pain on categorical pain scale (46 vs. 6%; p &lt; 0.01) 3) Reduction in pain on VAS (54 vs. 6%; p &lt; 0.02) 4) Reduction of &gt;40% on pain relief scale (31 vs. 1%; p &lt; 0.05)</td>
<td>Burning, stinging and/or erythema at application site in a number of patients</td>
</tr>
<tr>
<td>The Capsaicin Study Group [45], 1991</td>
<td>Randomized, double-blind, vehicle-controlled multicenter study in PDN</td>
<td>Capsaicin cream 0.075% w/w vs. vehicle 4 times daily for 8 weeks</td>
<td>252</td>
<td>1) Physician Global Evaluation: more capsaicin- than vehicle-treated patients improved at week 8 (69.5 vs. 53.4%; p &lt; 0.05) 2) Patient-rated pain intensity and pain relief: significantly more capsaicin- than vehicle-treated patients improved at week 8 (38.1 vs. 27.4% and 58.4 vs. 45.3%, respectively)</td>
<td>Capsaicin cream associated with transient burning, wheezing and coughing</td>
</tr>
<tr>
<td>Watson et al. [46], 1993</td>
<td>Randomized, double-blind, vehicle-controlled study in PHN</td>
<td>Capsaicin cream 0.075% w/w vs. vehicle 4 times daily for 6 weeks</td>
<td>143</td>
<td>1) Improvement in physician global response at week 6 (64 vs. 25%; p &lt; 0.014) 2) Reduction in pain on categorical pain scale at week 6 (39 vs. 6%; p &lt; 0.006) 3) Percentage decrease in pain on VAS at week 6 (15 vs. 5%; p &lt; 0.05)</td>
<td>Improvements were statistically significant or close to statistical significance at all time points during the study</td>
</tr>
<tr>
<td>Biesbroeck et al. [47], 1995</td>
<td>Randomized, double-blind, multicenter, parallel study in PDN</td>
<td>Capsaicin cream 0.075% w/w vs. amitriptyline for 8 weeks</td>
<td>235</td>
<td>1) At the end of week 8, 76% of patients in both capsaicin and amitriptyline groups had less pain with a mean reduction in intensity of &gt;40% 2) At the end of week 8, interference with daily activities by pain, including sleeping and walking, had significantly reduced in both groups (p = 0.001)</td>
<td>Capsaicin cream was equally effective as amitriptyline in providing pain relief to patients with PDN</td>
</tr>
<tr>
<td>Ellison et al. [48], 1997</td>
<td>Randomized, double-blind, placebo-controlled, crossover study in postsurgical neuropathic pain</td>
<td>Capsaicin cream 0.075% w/w vs. placebo 4 times daily for 8 weeks</td>
<td>99</td>
<td>1) Average pain reduction at week 8 favored the capsaicin arm (53 vs. 17%; p &lt; 0.001) 2) At end of study (week 16), 60 vs. 18% of patients preferred capsaicin cream to placebo, and 22% chose neither treatment (p = 0.001)</td>
<td>Short-term use of capsaicin cream demonstrated efficacy in postsurgical neuropathic pain after 4 weeks of treatment but it was associated with skin burning, skin redness and coughing (which occurred throughout the study)</td>
</tr>
<tr>
<td>Reference</td>
<td>Study design</td>
<td>Intervention</td>
<td>Sample size, n</td>
<td>Main study results</td>
<td>Comment</td>
</tr>
<tr>
<td>----------------------------</td>
<td>---------------------------------------------------</td>
<td>--------------------------------------------------------</td>
<td>----------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Paice et al. [49], 2000</td>
<td>Randomized, controlled, double-blind, multicenter study in HIV-AN</td>
<td>Capsaicin cream 0.075% w/w or vehicle 4 times daily for 4 weeks</td>
<td>26</td>
<td>1) At the end of 1 week, patients receiving capsaicin reported higher current pain scores than their counterparts &lt;br&gt;2) The dropout rate was higher for the capsaicin group (67%) than for the vehicle group (18%) &lt;br&gt;3) There were no statistically significant differences between the capsaicin and vehicle groups with respect to current pain, worst pain, pain relief, sensory perception (touch pressure), quality of life, mood or function</td>
<td>Low-concentration capsaicin was ineffective for the treatment of HIV-AN</td>
</tr>
<tr>
<td>Webster et al. [50], 2010</td>
<td>Randomized, double-blind, multicenter study in PHN</td>
<td>Single application of capsaicin 8% w/w patch or capsaicin 0.04% w/w control patch for 30, 60 or 90 min</td>
<td>299</td>
<td>1) Mean percent reductions in NPRS score from baseline to weeks 2–8 were greater in the pooled capsaicin 8% w/w patch groups (26.5%; p = 0.0286) and the 90-min capsaicin 8% w/w patch group (27.8%; p = 0.0438) vs. the pooled control group (17.3%). &lt;br&gt;2) Post hoc gender-stratified analyses showed that the 60-min capsaicin 8% w/w patch group had a larger mean percent reduction in average pain scores compared with the pooled control group (28.0 vs. 17.2%; p = 0.0331) &lt;br&gt;3) Treatment with capsaicin 8% w/w patch did not result in detectable changes in allodynia, light brush, pinprick, vibration or warmth sensations</td>
<td>1) Treatment was well tolerated &lt;br&gt;2) Responses to PHN pain treatment are influenced by gender. Future randomized controlled studies should control for this covariate at baseline during the stratification process</td>
</tr>
<tr>
<td>Backonja et al. [51], 2008</td>
<td>Randomized, double-blind, multicenter study in PHN</td>
<td>Single 60-min application of capsaicin 8% w/w patch or capsaicin 0.04% w/w control patch</td>
<td>402</td>
<td>1) Mean change in NPRS score during weeks 2–8 favored capsaicin 8% w/w patch (–29.6 vs. –19.9%; p = 0.001) &lt;br&gt;2) Mean change in NPRS score during weeks 2–12 favored capsaicin 8% w/w patch (–29.9 vs. –20.4%; p = 0.002) &lt;br&gt;3) 42% of capsaicin 8% w/w patch patients vs. 32% of control patients had a ≥30% reduction in mean NPRS score (OR 1.56; 95% CI 1.03–2.37; p = 0.03) &lt;br&gt;4) No between-group differences with respect to QST examinations (light brush, pinprick, warmth, vibration and allodynia) at weeks 4, 8 and 12 post-application</td>
<td>1) Rapid and long-lasting response associated with capsaicin 8% w/w patch &lt;br&gt;2) Capsaicin 8% w/w patch generally well tolerated with AEs limited to short-term application-site reactions</td>
</tr>
<tr>
<td>Backonja et al. [52], 2010</td>
<td>Randomized, double-blind followed by open-label extension study in PHN</td>
<td>Up to three 60-min applications of capsaicin 8% w/w patch after an initial double-blind capsaicin 8% w/w patch treatment (cycle 0)</td>
<td>21</td>
<td>1) Mean change in NPRS scores over 48 weeks: cycle 0 (–33.8%, n = 13), cycle 1 (–31.4%, n = 21), cycle 2 (–30.0%, n = 15), and cycle 3 (–34.1%, n = 9) &lt;br&gt;2) Sensory examinations (sharp and dull stimuli) of the treated areas and determination of percentage of allodynia in painful areas were highly variable, with no evident trend over the course of this study that would indicate sensory nerve damage with repeated treatment</td>
<td>1) Durable efficacy on repeated applications, high level of patient adherence and patient acceptance of treatment &lt;br&gt;2) Treatment was well tolerated, with no increase in application-site reactions or AEs observed with repeated treatments</td>
</tr>
<tr>
<td>Simpson et al. [53], 2008</td>
<td>Randomized, controlled, double-blind, multicenter study in HIV-DSP</td>
<td>Single application of capsaicin 8% w/w patch or capsaicin 0.04% w/w control patch for 30, 60 or 90 min</td>
<td>307</td>
<td>1) Mean change in NPRS score during weeks 2–12 favored capsaicin 8% w/w patch (–22.8 vs. –10.7%; p = 0.0026) &lt;br&gt;2) Significant analgesia was apparent by week 2 &lt;br&gt;3) Mean pain reductions in the capsaicin 8% w/w patch 30-, 60- and 90-min groups were 27.7, 15.9 and 24.7%, respectively (p = 0.0007, p = 0.027 and p = 0.0046, respectively, vs. control) &lt;br&gt;4) 42% of patients treated with capsaicin 8% w/w patch for 30 min reported ≥30% pain decrease from baseline vs. 18% of controls (p = 0.01) &lt;br&gt;5) No detectable QST (cool, warm, sharp, heat-pain, vibratory sensations or deep tendon reflexes) changes associated with capsaicin 8% w/w patch</td>
<td>1) The only treatment to have meaningful efficacy for this neuropathy &lt;br&gt;2) The recommended application time of capsaicin 8% w/w patch for treatment of HIV-AN is 30 min &lt;br&gt;3) Capsaicin 8% w/w patch generally well tolerated, with AEs limited to short-term application-site reactions</td>
</tr>
</tbody>
</table>
The rate and magnitude of reversible neurite degeneration was demonstrated in skin biopsies of healthy volunteers who received either repeated topical applications of low-concentration capsaicin cream (0.075%, w/w) or a single application of high-concentration capsaicin patch (8%, w/w). Overall, the reduction in ENF density was slower and less extensive after repeated application of the low-concentration capsaicin creams than after a single application of the high-concentration capsaicin patch (Table 1).

Sensory testing revealed a pronounced reduction in thermal pain sensitivity but not pinprick sensitivity within the first few days after high-dose capsaicin cream, consistent with animal data. One week after application of the high-dose patch, however, thermal pain sensitivity was normal, suggesting relatively rapid recovery of nociceptive function in healthy subjects. A study using laser-evoked potentials and skin biopsies after low-dose capsaicin cream treatment also found a more rapid recovery of thermal pain sensation than ENF density.

The laser-evoked potential data indicate that heat-sensitive A-fiber nociceptors are also defunctionalized by capsaicin, whereas capsaicin was not associated with alterations in light touch, deep pain or mechanical pain detection thresholds. Sharp mechanical (pinprick) pain is primarily mediated via capsaicin-insensitive A-fiber nociceptors, which would explain why topical capsaicin had only modest effects on this stimulus.

Therapeutic Use

Low-Concentration Topical Capsaicin

Despite promising pharmacodynamic data describing hypalgesia accompanied by ENF degeneration in human volunteers [10], low-concentration capsaicin creams (≤0.0.1%) have demonstrated poor-to-modest efficacy in metastatic pain syndromes over the short-term (Table 1). Explanations for the disappointing results include the low concentrations used and poor patient adherence [9, 66-68]. More recently, a dermal patch has been developed containing a high-concentration of synthetic pure-trans-capsaicin (10%). This product demonstrated a rapid onset of pain relief in patients with intractable pain due to peripheral neuropathy or post-herpetic neuralgia [11].

High-Concentration Topical Capsaicin

High-concentration topical capsaicin was first used as a 10% w/v solution in 10 patients with intractable pain due to bilateral peripheral neuropathy but this approach was terminated due to severe pain on application (despite regional analgesia) and risk of aerosol contamination [12]. More recently, a dermal patch has been developed containing a high-concentration of synthetic pure-trans-capsaicin (10%). This product demonstrated a rapid onset of pain relief in patients with intractable pain due to peripheral neuropathy or post-herpetic neuralgia [11].

Table 1 (continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>Intervention</th>
<th>Sample size, n</th>
<th>Main study results</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robbins et al. [16], 1998</td>
<td>Open-label, single-center study in refractory foot or chest wall pain</td>
<td>Single application of capsaicin cream 5–10% w/w</td>
<td>10</td>
<td>Efficacy demonstrated based on VAS</td>
<td>Data infer potential clinical utility of high-dose capsaicin in a variety of refractory pain conditions</td>
</tr>
<tr>
<td>Simpson et al. [54], 2010</td>
<td>Open-label, extension study in PHN or HIV-DSP</td>
<td>Up to 3 applications of capsaicin 8% w/w patch at intervals ≥12 weeks after an initial capsaicin 8% w/w patch treatment</td>
<td>106</td>
<td>1) The most frequently reported AEs were transient, mild-to-moderate application-site erythema, pain, edema and papules 2) Small, transient pain-related increases in blood pressure were observed during and immediately after capsaicin 8% w/w patch application 3) No evidence of increased incidence of AEs, intolerance, and neurological or sensory (deep tendon reflexes, vibration, and warmth and sharp sensation for HIV-DSP patients and light brush, pinprick, warmth and vibration for PHN patients) impairment with repeated treatments</td>
<td>Over a 1-year period repeated capsaicin 8% w/w patch treatments generally have a good safety and tolerability profile</td>
</tr>
</tbody>
</table>

* Patients received concomitant neuropathic pain medications. † Patients were pretreated with topical lidocaine 4% w/w for 1 h. ‡ Treatment was administered to patients under regional anesthesia. AE = Adverse event; DTX = diphtheria toxin; HIV-AN = HIV-associated peripheral neuropathy; HIV-DSP = HIV-associated distal sensory polyneuropathy; LEP = laser-evoked potential; Mrgprd = Mas-related G protein-coupled receptor D; NPRS = Numeric Pain Rating Scale; P DN = painful diabetic neuropathy; QST = quantitative sensory testing; VAS = visual analog scale.
Capsaicin (8% w/w) in the adhesive layer (QUTENZA™; NGX-4010). Advances in stereoselective medicinal chemistry have facilitated synthesis of pure trans-capsaicin (99%), which is identical to the naturally occurring molecule [9, 67]. The synthetic process delivers higher concentrations of active trans-capsaicin than can be extracted from capsicums [67]. The high-concentration patch demonstrated efficacy in patients with PHN and in those with HIV-associated distal sensory neuropathy (HIV-DSP) (table 1) [51–54]. Lack of unnecessary exposure to capsaicin during the application and removal procedure represents a practical tolerability advantage of the patch over capsaicin creams. In addition, only one treatment is required every 3 months (or longer depending on pain control status).

In contrast to the clinical trial data for low-concentration capsaicin creams, the clinical efficacy data for the 8% capsaicin patch are entirely consistent with skin biopsy data. In double-blind randomized trials that used a low-dose capsaicin patch (0.04% w/w) as an active control to maintain blinding, a single application of the 8% capsaicin patch produced rapid and prolonged pain relief in patients with moderate-to-severe PHN or HIV-DSP, irrespective of whether they were receiving concomitant medications for neuropathic pain (table 1) [51–53].

A 60-min application of the 8% capsaicin patch – shown to be effective in patients with PHN [50] – exerted its maximum therapeutic effect as early as 2 days after application [51]. Significantly more patients treated with the 8% capsaicin patch reported a ≥30% pain decrease from baseline than control patients (42 vs. 32%; p = 0.04) [51]. Furthermore, the proportion of patients reporting an improvement on the Patient Global Impression of Change scale was significantly higher among those treated with the 8% capsaicin patch compared with those treated with the control at both week 8 (53 vs. 42%; p = 0.03) and week 12 (55 vs. 43%; p = 0.04) [51]. Similarly, a dose-finding study in patients with HIV-DSP revealed that a single 30- or 120-min (but not 60-min) application of the 8% capsaicin patch provided meaningful pain relief within 2 weeks, which persisted throughout the 12-week observation period [53]. The proportion of patients who reported a ≥30% pain decrease from baseline was ≥2-fold greater in the group treated with the 8% capsaicin patch than the control group (42 vs. 18%; p = 0.01) [53]. The importance of these positive trial data cannot be understated as there are very few, if any, other treatments with proven effectiveness in HIV-DSP [69]. Two open-label studies, which followed patients for a total of 48 weeks after their first treatment, have shown that re-application of the 8% capsaicin patch results in reproducible tolerability and safety, and suggest that a comparable degree of pain relief can be achieved with each retreatment (table 1) [52, 54].

The clinical efficacy of the 8% capsaicin patch for treatment of PHN and HIV-DSP has been confirmed in two independent meta-analyses [70, 71] and the European Federation of Neurological Societies have included the 8% capsaicin patch in recent guidelines on the pharmacological treatment of neuropathic pain [69]. Further studies are now needed to identify those patients who get the most pain relief and to identify other peripheral neuropathic pain syndromes that may respond to treatment with the 8% capsaicin patch. Patients with heat hyperalgasia, who make up about 18% of patients with neuropathic pain [72], are likely candidates.

Capsaicin Safety

Intradermal capsaicin administration leads to irreversible loss of TRPV1 neurons due to systemic distribution in newborn rodents [73, 74], and to transient TRPV1 denervation at the injection site in human adults [75]. Repeated, long-term application of topical capsaicin to the rat hind paw did not damage the sciatic nerve or result in neuron loss in the dorsal root ganglion [76].

High-level dietary intake of capsaicin is not associated with any safety concerns in humans. The estimated highest capsaicin dietary exposure (in India, Mexico and Thailand) is 25–200 mg/day [77] and the total capsaicin content of one 8% capsaicin patch is within that range (179 mg per patch, of which only a fraction is absorbed). Systemic absorption of capsaicin is very low following a 60- or 90-min application of the 8% capsaicin patch, with a maximum plasma concentration of 17.8 ng/ml observed in any patient [78]. Systemic exposure to capsaicin following 8% capsaicin patch application is also transient as capsaicin levels decline rapidly with a mean population elimination half-life of 1.6 h. Furthermore, detectable levels of capsaicin metabolites were not observed in any patients. Therefore, treatment with the 8% capsaicin patch is unlikely to result in systemic side effects or to alter the systemic metabolism of concomitant medications. In clinical trials, topical application of capsaicin was generally well tolerated and associated with transient application-site reactions such as pain and erythema (table 1).

It is important to evaluate the safety of topical capsaicin in patients with diabetes as they likely have ongoing neurodegenerative processes that might be exacerbated by capsaicin. Case-control data indicate that ENF regeneration after low-dose capsaicin is slower among patients
with diabetes even when these patients had no evidence of neuropathy [79]. Moreover, caution should be exercised when applying topical capsaicin to skin at risk of ulceration [80]. Two small studies of patients with painful diabetic neuropathy reported the encouraging finding that topical capsaicin cream had no adverse effects on sensory function or neurovascular control [81, 82], but more safety data, using both morphological (ENF) and functional assessments (heat pain, laser-evoked potentials), are needed before this treatment can be recommended for patients with diabetes (currently a contraindication).

Discussion

A better understanding of the molecular and cellular effects of capsaicin has helped rationalize the popularity of this molecule as a means of assuaging pain. Theories on the mechanism of action of capsaicin have shifted from increased perfusion and counterirritation to defunctionalization. Defunctionalization of the entire population of TRPV1-expressing neurons is more efficient in reducing pain behavior in animals than knockout of TRPV1. Likewise in humans, defunctionalization by high-dose patches has been found effective in meta-analyses of clinical trials, whereas TRPV1-antagonists have yet to be approved (they are also burdened by adverse effects such as fever, hypertension and gastric ulceration [29]). Both low-dose and high-dose topical capsaicin are listed as effective in the most recent meta-analysis on neuropathic pain therapy [71]. Of all the effective therapies, the high-dose patch is unique in that it can deliver up to 12 weeks of pain relief from a single application, whereas all other therapies were evaluated for continuous treatment over the same period of time. At the clinic, activation of TRPV1 by topical application of the 8% capsaicin patch translated into meaningful pain relief from PHN and HIV-DSP.

In conclusion, the capsaicin story is a valuable case study describing how pharmacognosy can provide valuable and necessary inputs into rational drug design, and how medicinal chemistry and neurobiology can improve traditional medicines. For the capsaicin patch, the difficult step of translating efficacy in defunctionalizing nociceptive neurons in animal models to pain relief in human patients was greatly facilitated by pre-existing clinical experience with topical capsaicin preparations that had been in use before the understanding of its molecular basis of action.

Acknowledgements

Editorial assistance and evidence tables were provided by Malcolm Darkes at Adelphi Communications, supported by Astellas Europe Ltd.

Disclosure Statement

M.H. has lectured or served on advisory boards for the following companies in the past 24 months: Abbott, Astellas, AstraZeneca, Eli Lilly, Janssen Cilag, Medtronic, MSD, Mundipharma, Pfizer and Sanofi-Pasteur, and has participated in international congresses as a guest of Astellas, Medtronic and Pfizer. RDT has lectured or served on advisory boards for or received grants from the following companies in the past 24 months: Astellas, Boehringer Ingelheim, Galderma, Grünenthal, Kade, Eli Lilly, Merz, Nycomed, Pfizer.

References


21 Lam VY, Wallace M, Schulteis G: Effects of
20 NeurogesX Inc: Investigators Brochure:
19 Astellas Pharma Europe Ltd: Summary of
18 NeurogesX Inc: Antinociceptive capsaicin analogues: studies
17 Magerl W, Fuchs PN, Meyer RA, Treede RD:
16 Robbins WR, Staats PS, Levine J, Fields HL,
15 Friens J, Appindido G, Nilius B: Pharmacology of vanilloid transient receptor potential channel proteins. Mol Pharmacol 2009;75:
14 Dray A, Bettaney J, Rueff A, Walpole C,
1262–1279.
124: 1754–1764.
123: 1228–1237.
122: 579–583.
121: 1754–1764.
120: 306–313.
119: 368–376.
114: 525–530.
113: 265–270.
111: 360–367.
106: 151–2225–2229.
104: 972–982.
101: 587–583.
100: 183–187.
100: 1754–1764.
98: 531–543.
97: 1228–1237.
95: 317–328.
94: 2225–2229.
Capsaicin for Neuropathic Pain Control

Eur Neurol 2012;68:264–275


